Cyrano Therapeutics
- Biotech or pharma, therapeutic R&D
Cyrano is leveraging an innovative and proprietary olfactory-directed intranasal "mist"technology to safely deliver effective medicines for the treatment of ENT, allergy, and respiratory conditions with significant unmet need. The lead program, CYR-064, is targeting Phase 2 data in 2H25 as the potential first-to-market for post-viral hyposmia (loss of smell). The company estimates ~60M patients with persistent hyposmia (3+ months) across U.S., EU, and Japan. CYR-064 is also in a pilot study for the treatment of Parkinson's Disease associated hyposmia. Cyrano is seeking to engage potential partners and investors.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}